Literature DB >> 12673202

E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines.

Marcella Flinterman1, Joop Gäken, Farzin Farzaneh, Mahvash Tavassoli.   

Abstract

Previous studies have shown early region 1A (E1A) gene to inhibit the proliferation of tumour cells with wild-type, but not mutant, p53. E1A has also been shown to downregulate c-erb-B-2/neu expression, resulting in inhibition of growth in c-erb-B-2/neu overexpressing tumour cells. In this study, we have investigated the effect of E1A expression on four head and neck squamous cell carcinoma (HNSCC) cell lines that do not overexpress c-erb-B-2/neu. Cell cycle and Western blot analysis show E1A-mediated induction of apoptosis in all cell lines examined. This induction of apoptosis was independent of the p53 status as it occurred in the cell lines with wild-type, mutated or deleted p53. However, there was no evidence of E1A-induced apoptosis in a p53(+ve) normal human fibroblast cell line, 1BR3. Analysis of apoptosis in the SCC cell lines demonstrated E1A-mediated downregulation of EGFR, which was overexpressed in each of these cell lines. Overexpression of an exogenously introduced EGFR, under the control of an E1A-insensitive heterologous promoter, blocked E1A induction of apoptosis in these cells. Therefore, E1A-mediated downregulation of EGFR expression appears to be the cause, rather than a consequence of E1A-induced apoptosis in these SCC cell lines. Previous studies have shown downregulation of EGFR expression by PML. Interestingly, E1A expression in the HNSCC cells altered the pattern of PML distribution and induced the level of PML protein, thus suggesting that E1A-mediated downregulation of EGFR may occur via direct or indirect interactions with PML. These findings demonstrate a novel pathway by which E1A can induce apoptosis and identify EGFR as a potential target for the development of therapeutic strategies against epithelial malignancies, the majority of which have abnormal EGFR expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673202     DOI: 10.1038/sj.onc.1206190

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing.

Authors:  M B Flinterman; J S Mymryk; P Klanrit; A F Yousef; S W Lowe; C Caldas; J Gäken; F Farzaneh; M Tavassoli
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

2.  Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5.

Authors:  S Vijayalingam; T Subramanian; Jan Ryerse; Mark Varvares; G Chinnadurai
Journal:  Virology       Date:  2009-07-24       Impact factor: 3.616

3.  PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers.

Authors:  P Klanrit; P Taebunpakul; M B Flinterman; E W Odell; M A Riaz; G Melino; P Salomoni; J S Mymryk; J Gäken; F Farzaneh; M Tavassoli
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

4.  E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization.

Authors:  María Llanos Valero; Francisco Jose Cimas; Laura Arias; Pedro Melgar-Rojas; Elena García; Juan Luis Callejas-Valera; Jesús García-Cano; Leticia Serrano-Oviedo; Miguel Ángel de la Cruz-Morcillo; Isabel Sánchez-Pérez; Ricardo Sánchez-Prieto
Journal:  Cell Cycle       Date:  2013-10-11       Impact factor: 4.534

5.  Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin.

Authors:  Poramaporn Klanrit; Marcella B Flinterman; Edward W Odell; Gerry Melino; Richard Killick; James S Norris; Mahvash Tavassoli
Journal:  Cell Cycle       Date:  2007-11-16       Impact factor: 4.534

6.  Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.

Authors:  Shuhei Osaki; Hiroshi Tazawa; Joe Hasei; Yasuaki Yamakawa; Toshinori Omori; Kazuhisa Sugiu; Tadashi Komatsubara; Tomohiro Fujiwara; Tsuyoshi Sasaki; Toshiyuki Kunisada; Aki Yoshida; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

7.  A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.

Authors:  Chih-Ming Su; Ting-Yu Chang; Hui-Ping Hsu; Hui-Huang Lai; Jie-Ning Li; Yu-Jhen Lyu; Kuang-Tai Kuo; Ming-Te Huang; Jen-Liang Su; Pai-Sheng Chen
Journal:  Oncotarget       Date:  2016-09-27

Review 8.  Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death.

Authors:  Jasmine Wyatt; Manuel M Müller; Mahvash Tavassoli
Journal:  Cancers (Basel)       Date:  2019-12-07       Impact factor: 6.639

9.  Identification of genes differentially expressed as result of adenovirus type 5- and adenovirus type 12-transformation.

Authors:  Janet Strath; Lindsay J Georgopoulos; Paul Kellam; G Eric Blair
Journal:  BMC Genomics       Date:  2009-02-06       Impact factor: 3.969

10.  Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model.

Authors:  S Vijayalingam; Mohan Kuppusamy; T Subramanian; Frank F Strebeck; Cheri L West; Mark Varvares; G Chinnadurai
Journal:  Cancer Gene Ther       Date:  2014-05-30       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.